KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 78 filers reported holding KINNATE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,489,941 | -55.0% | 1,064,243 | -2.6% | 0.00% | -100.0% |
| Q2 2023 | $3,311,748 | -50.9% | 1,092,986 | +1.2% | 0.00% | 0.0% |
| Q1 2023 | $6,749,057 | +0.2% | 1,079,849 | -2.2% | 0.00% | -50.0% |
| Q4 2022 | $6,732,411 | -49.6% | 1,103,674 | -1.3% | 0.00% | -33.3% |
| Q3 2022 | $13,362,000 | -7.8% | 1,118,101 | -2.7% | 0.00% | -25.0% |
| Q2 2022 | $14,496,000 | +11.2% | 1,149,489 | -0.7% | 0.00% | +33.3% |
| Q1 2022 | $13,041,000 | -34.4% | 1,158,154 | +3.2% | 0.00% | -25.0% |
| Q4 2021 | $19,876,000 | -25.2% | 1,121,704 | -2.8% | 0.00% | -33.3% |
| Q3 2021 | $26,571,000 | -12.3% | 1,154,273 | -11.3% | 0.01% | -14.3% |
| Q2 2021 | $30,285,000 | -26.1% | 1,300,887 | -1.1% | 0.01% | -30.0% |
| Q1 2021 | $40,996,000 | -21.7% | 1,315,650 | +0.0% | 0.01% | -28.6% |
| Q4 2020 | $52,331,000 | – | 1,315,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |